Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755236 | 1.00 | ACHE (0.50) | ACHESIGMAR1RAB9AKCNH2KMT2A | |
| SCHEMBL11790566 | 0.79 | LMNA (0.46) | ACHESIGMAR1KMT2AALDH1A1 | |
| SCHEMBL7983264 | 0.77 | CYP2D6 (0.57) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL4373217 | 0.75 | SIGMAR1 (0.56) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL791288 | 0.75 | CYP2D6 (0.55) | SIGMAR1ALDH1A1 | |
| SCHEMBL17828183 | 0.74 | ACHE (0.71) | ACHESIGMAR1KCNH2 | |
| SCHEMBL11790830 | 0.73 | LMNA (0.64) | SIGMAR1KMT2A | |
| SCHEMBL15308540 | 0.73 | CYP2A13 (0.66) | SIGMAR1KMT2A | |
| SCHEMBL18934284 | 0.72 | SIGMAR1 (0.51) | ACHESIGMAR1 | |
| SCHEMBL29048070 | 0.69 | GBA1 (0.52) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |